Immunic announced first patients enrolled in investigator-sponsored phase 2 clinical trial of IMU-838 in combination with Oseltamivir for treatment of patients with COVID-19
|

Immunic announced first patients enrolled in investigator-sponsored phase 2 clinical trial of IMU-838 in combination with Oseltamivir for treatment of patients with COVID-19

On Jul. 27, 2020, Immunic announced enrollment of the first patients in an investigator-sponsored phase 2 clinical trial…

Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers formed collaboration to develop Emergent’s COVID-19 hyperimmune globulin product
| |

Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers formed collaboration to develop Emergent’s COVID-19 hyperimmune globulin product

On Jul. 8, 2020, the Mount Sinai Health System, Emergent BioSolutions and ImmunoTek Bio Centers announced a collaboration…